MarketBeat
20 Nov 2026, 05:13 UTC · 1h ago
BioCryst Pharmaceuticals Sees Revenue Near Top of Guidance as It Expands HAE Portfolio
Impact · against what's priced in
BioCryst is showing positive momentum through revenue guidance beats and successful pediatric expansion of ORLADEYO. The primary value catalysts are now the Q3 2027 pivotal data for navenibart and the upcoming Netherton syndrome results, both of which offer paths to expand the addressable market.
- BCRX+0.50
No priced-in read yet





